Skip to main content
InnoCare Pharma Limited logo

InnoCare Pharma Limited — Investor Relations & Filings

Ticker · 9969 ISIN · KYG4783B1032 LEI · 3003001NYJPPWIEOJT79 HKEX Manufacturing
Open in API
Filings indexed 428 across all filing types
Latest filing 2026-03-25 Governance Information
Country KY Cayman Islands
Listing HKEX 9969

About InnoCare Pharma Limited

http://www.innocarepharma.com

InnoCare Pharma Limited is a commercial stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs. The company focuses primarily on creating potentially best-in-class and first-in-class therapies for the treatment of cancer (oncology) and autoimmune diseases. InnoCare researches, develops, and commercializes its pipeline with the goal of delivering safe and effective treatments to patients globally.

Recent filings

Filing Released Lang Actions
TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE
Governance Information Classification · 1% confidence The document is the Terms of Reference for the Nomination Committee, which sets out internal governance rules, board composition, committee duties, meeting procedures, and authority delegated by the Board. It is a detailed governance charter, not an announcement of results or financial report. This fits the Governance Information category.
2026-03-25 English
TERMS OF REFERENCE FOR THE COMPENSATION COMMITTEE
Governance Information Classification · 1% confidence The document is the formal “Terms of Reference for the Compensation Committee,” detailing the committee’s constitution, duties, membership, meeting procedures, authority, and reporting lines. This is a governance charter outlining internal rules and board committee structure rather than financial results, transactions, or management announcements. It fits the Governance Information category (CGR).
2026-03-25 English
TERMS OF REFERENCE FOR THE AUDIT COMMITTEE
Governance Information Classification · 1% confidence The document is the charter/terms of reference for the company’s Audit Committee, detailing governance structure, membership, authority, duties, and procedures. It is not an audit report of financial statements, not an announcement of results, and not a proxy or remuneration statement. It clearly falls under governance information outlining internal rules and board/committee practices.
2026-03-25 English
ANNOUNCEMENT ON PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 1% confidence The document is an announcement by a Hong Kong–listed company under Listing Rule 13.51(1) proposing specific amendments to its Memorandum & Articles of Association (M&A). It includes a detailed table comparing existing vs. new Articles, but is not announcing voting results nor actual issuance of new securities, nor is it an earnings or interim report. It is not simply a brief report‐publication notice; rather, it provides substantial governance content about internal rules. Therefore it aligns with the Governance Information category (CGR).
2026-03-25 English
CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT
Board/Management Information Classification · 1% confidence The document is an official announcement on the Hong Kong Stock Exchange regarding the resignation and appointment of the company secretary, authorised representative and process agent – a change in senior management roles. This fits the “Board/Management Information” category for announcements of changes in board or senior management (Code: MANG).
2026-03-25 English
UPDATE IN USE OF PROCEEDS OF RMB SHARE ISSUE
Capital/Financing Update Classification · 1% confidence The document is a formal announcement by InnoCare Pharma Limited providing an update on the use of proceeds from a previously completed RMB share issue, detailing adjustments to the internal investment structure of fundraising projects and how the net proceeds will now be allocated. It does not present full financial statements (so it’s not an Interim or Annual Report), nor is it a one‐time earnings highlight (Earnings Release), nor a notice of dividends or board changes. Instead, it specifically updates shareholders on how fundraising capital is to be deployed, fitting the “Capital/Financing Update” category.
2026-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.